Allergy
-
Clinical Trial
Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.
Schnitzler syndrome (SchS) is a rare disease with suspected autoinflammatory background that shares several clinical symptoms, including urticarial rash, fever episodes, arthralgia, and bone and muscle pain with cryopyrin-associated periodic syndromes (CAPS). Cryopyrin-associated periodic syndromes respond to treatment with interleukin-1 antagonists, and single case reports of Schnitzler syndrome have shown improvement following treatment with the interleukin-1 blocker anakinra. This study evaluated the effects of the interleukin-1 antagonist rilonacept on the clinical signs and symptoms of SchS. ⋯ Rilonacept was effective and well tolerated in patients with SchS and may represent a promising potential therapeutic option.